Najean Y
Department of Nuclear Medicine and Haematology, St Louis Hospital, Paris, France.
Med Oncol Tumor Pharmacother. 1987;4(3-4):245-57. doi: 10.1007/BF02934521.
A short review, limited to recently published series of data, has been compiled on the 'therapy-induced' secondary malignancies. Their frequency, peak of incidence, haematological and clinical criteria, the influence of age, treated primary disease, choice of drug(s) and modality of prescription and the role of genetic and environmental factors are analyzed. The risk varies between 0.6 and 20.5% after different treatment forms. Some suggestions for the choice of treatment of chronic malignant disorders, and for the design of future epidemiological studies are given.
本文对“治疗诱发”的继发性恶性肿瘤进行了简短综述,仅涵盖近期发表的系列数据。分析了其发生率、发病高峰、血液学和临床标准、年龄的影响、所治疗的原发性疾病、药物选择及处方方式,以及遗传和环境因素的作用。不同治疗方式后的风险在0.6%至20.5%之间变化。文中还给出了一些关于慢性恶性疾病治疗选择及未来流行病学研究设计的建议。